Intercept to Present at Upcoming Investor Conferences
- Baird 2018 Global Healthcare Conference at
10:50 a.m. ETon Wednesday, September 5, 2018;
- 16th Annual
Morgan Stanley Global Healthcare Conferenceat 11:05 a.m. ETon Friday, September 14, 2018.
Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in
For more information about Intercept, please contact:
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.